These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 18096436

  • 1. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene.
    King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M, Atkinson MA, Wasserfall C, Herold KC, Woodland RT, Schmidt MR, Woda BA, Thompson MJ, Rossini AA, Greiner DL.
    Clin Immunol; 2008 Mar; 126(3):303-14. PubMed ID: 18096436
    [Abstract] [Full Text] [Related]

  • 2. Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice.
    Banuelos SJ, Shultz LD, Greiner DL, Burzenski LM, Gott B, Lyons BL, Rossini AA, Appel MC.
    Clin Immunol; 2004 Sep; 112(3):273-83. PubMed ID: 15308121
    [Abstract] [Full Text] [Related]

  • 3. Development of new-generation HU-PBMC-NOD/SCID mice to study human islet alloreactivity.
    King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M, Atkinson M, Wasserfall C, Herold K, Mordes JP, Rossini AA, Greiner DL.
    Ann N Y Acad Sci; 2007 Apr; 1103():90-3. PubMed ID: 17376822
    [Abstract] [Full Text] [Related]

  • 4. Human peripheral blood lymphocyte reconstituted severe combined immunodeficient (hu-PBL-SCID) mice. A model for human islet allograft rejection.
    Shiroki R, Poindexter NJ, Woodle ES, Hussain MS, Mohanakumar T, Scharp DW.
    Transplantation; 1994 Jun 15; 57(11):1555-62. PubMed ID: 8009588
    [Abstract] [Full Text] [Related]

  • 5. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R.
    J Immunol; 2009 Oct 01; 183(7):4782-91. PubMed ID: 19748990
    [Abstract] [Full Text] [Related]

  • 6. Humanized NOD/LtSz-scid IL2 receptor common gamma chain knockout mice in diabetes research.
    Shultz LD, Pearson T, King M, Giassi L, Carney L, Gott B, Lyons B, Rossini AA, Greiner DL.
    Ann N Y Acad Sci; 2007 Apr 01; 1103():77-89. PubMed ID: 17332083
    [Abstract] [Full Text] [Related]

  • 7. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.
    Pino S, Brehm MA, Covassin-Barberis L, King M, Gott B, Chase TH, Wagner J, Burzenski L, Foreman O, Greiner DL, Shultz LD.
    Methods Mol Biol; 2010 Apr 01; 602():105-17. PubMed ID: 20012395
    [Abstract] [Full Text] [Related]

  • 8. Characterization of the NOD/scid-[Tg]DR1 mouse expressing HLA-DRB1*01 transgene: a model of SCID-hu mouse for vaccine development.
    Camacho RE, Wnek R, Fischer P, Shah K, Zaller DM, Woods A, La Monica N, Aurisicchio L, Fitzgerald-Bocarsly P, Koo GC.
    Exp Hematol; 2007 Aug 01; 35(8):1219-30. PubMed ID: 17662890
    [Abstract] [Full Text] [Related]

  • 9. Efficient xenoengraftment in severe immunodeficient NOD/Shi-scid IL2rγnull mice is attributed to a lack of CD11c+B220+CD122+ cells.
    Ito R, Katano I, Ida-Tanaka M, Kamisako T, Kawai K, Suemizu H, Aiso S, Ito M.
    J Immunol; 2012 Nov 01; 189(9):4313-20. PubMed ID: 23018460
    [Abstract] [Full Text] [Related]

  • 10. Cellular-based therapies to prevent or reduce thrombocytopenia.
    Pineault N, Boyer L.
    Transfusion; 2011 Nov 01; 51 Suppl 4():72S-81S. PubMed ID: 22074630
    [Abstract] [Full Text] [Related]

  • 11. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice.
    Ito R, Katano I, Kawai K, Hirata H, Ogura T, Kamisako T, Eto T, Ito M.
    Transplantation; 2009 Jun 15; 87(11):1654-8. PubMed ID: 19502956
    [Abstract] [Full Text] [Related]

  • 12. Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment.
    Pearson T, Shultz LD, Miller D, King M, Laning J, Fodor W, Cuthbert A, Burzenski L, Gott B, Lyons B, Foreman O, Rossini AA, Greiner DL.
    Clin Exp Immunol; 2008 Nov 15; 154(2):270-84. PubMed ID: 18785974
    [Abstract] [Full Text] [Related]

  • 13. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice.
    Christianson SW, Greiner DL, Hesselton RA, Leif JH, Wagar EJ, Schweitzer IB, Rajan TV, Gott B, Roopenian DC, Shultz LD.
    J Immunol; 1997 Apr 15; 158(8):3578-86. PubMed ID: 9103418
    [Abstract] [Full Text] [Related]

  • 14. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
    Distler E, Wölfel C, Köhler S, Nonn M, Kaus N, Schnürer E, Meyer RG, Wehler TC, Huber C, Wölfel T, Hartwig UF, Herr W.
    Exp Hematol; 2008 Apr 15; 36(4):451-63. PubMed ID: 18261837
    [Abstract] [Full Text] [Related]

  • 15. Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation.
    Hexner EO, Danet-Desnoyers GA, Zhang Y, Frank DM, Riley JL, Levine BL, Porter DL, June CH, Emerson SG.
    Biol Blood Marrow Transplant; 2007 Oct 15; 13(10):1135-44. PubMed ID: 17889349
    [Abstract] [Full Text] [Related]

  • 16. NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant.
    Zhou W, Ohdan H, Tanaka Y, Hara H, Tokita D, Onoe T, Asahara T.
    Transpl Immunol; 2003 Oct 15; 12(1):9-18. PubMed ID: 14551028
    [Abstract] [Full Text] [Related]

  • 17. Human immune system development and rejection of human islet allografts in spontaneously diabetic NOD-Rag1null IL2rgammanull Ins2Akita mice.
    Brehm MA, Bortell R, Diiorio P, Leif J, Laning J, Cuthbert A, Yang C, Herlihy M, Burzenski L, Gott B, Foreman O, Powers AC, Greiner DL, Shultz LD.
    Diabetes; 2010 Sep 15; 59(9):2265-70. PubMed ID: 20570944
    [Abstract] [Full Text] [Related]

  • 18. Liposome-mediated transfer of IL-1 receptor antagonist gene to dispersed islet cells does not prevent recurrence of disease in syngeneically transplanted NOD mice.
    Saldeen J, Sandler S, Bendtzen K, Welsh N.
    Cytokine; 2000 Apr 15; 12(4):405-8. PubMed ID: 10805224
    [Abstract] [Full Text] [Related]

  • 19. Humanized SCID mouse models for biomedical research.
    Pearson T, Greiner DL, Shultz LD.
    Curr Top Microbiol Immunol; 2008 Apr 15; 324():25-51. PubMed ID: 18481451
    [Abstract] [Full Text] [Related]

  • 20. Abrogation of recurrent autoimmunity in the NOD mouse: A critical role for host interleukin 4.
    Shi Q, Wang D, Hadley GA, Farber DL, Bartlett ST.
    Surgery; 2006 Aug 15; 140(2):281-8. PubMed ID: 16904981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.